Tongli Pharmaceuticals (TGLP) Inactive 10-Q14 Nov 132014 Q2 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
Document And Entity Information	Sep. 30, 2013	Nov. 08, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'Tongli Pharmaceuticals (USA), Inc.	'
Entity Central Index Key	'0001052284	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'TGLP	'
Entity Common Stock, Shares Outstanding	'	14,728,111
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Mar. 31, 2013
ASSETS	'	'
Cash	$44,710	$80,618
Accounts receivable	1,262,039	2,966,435
Inventories	26,617	389,128
Advance to suppliers	37,610	43,685
Deferred tax assets	580,326	578,665
Prepaid expense and other current assets	3,895	11,151
Total current assets	1,955,197	4,069,682
Long-term assets:	'	'
Property and equipment, net	5,895,350	5,952,652
Intangible assets, net	3,222,725	3,276,958
Contract deposit-long term	10,533,864	8,760,731
Prepaid expense - noncurrent	37,938	0
Total long-term assets	19,689,877	17,990,341
Total assets	21,645,074	22,060,023
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable	13,211	355,407
Taxes payables	249,780	764,717
Accrued expenses	137,212	211,548
Due to related parties	431,893	261,196
Total current liabilities	832,096	1,592,868
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, authorized 1,000,000 shares; none issued and outstanding	0	0
Common stock, $0.001 par value, authorized 200,000,000 shares issued and outstanding 14,728,111 as of September 30, 2013 and March 31, 2013	14,728	14,728
Additional paid-in-capital	9,120,911	9,093,975
Retained earnings	8,783,407	8,902,347
Accumulated other comprehensive income	2,893,932	2,456,105
Total Stockholders' equity	20,812,978	20,467,155
Total liabilities and Stockholders' equity	$21,645,074	$22,060,023

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Sep. 30, 2013	Mar. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	14,728,111	14,728,111
Common stock, outstanding	14,728,111	14,728,111

CONSOLIDATED_STATEMENT_OF_COMP

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue	$0	$3,330,990	$753,079	$3,330,990
Cost of sales	0	1,747,908	380,303	1,747,908
Gross Profit	0	1,583,082	372,776	1,583,082
Operating expenses:	'	'	'	'
General and administrative expenses	151,150	130,122	305,099	633,715
Depreciation and amortization expenses	75,968	91,060	152,097	182,298
Selling expenses	1,894	213,852	8,248	232,918
Total operating expenses	229,012	435,034	465,444	1,048,931
Operating income(loss)	-229,012	1,148,048	-92,668	534,151
Other income(expenses):	'	'	'	'
Interest expense, net of interest income	-14,245	238	-26,796	263
Other income	24,346	0	48,530	0
Other expense	-24,916	0	-49,666	0
Total other income(expenses)	-14,815	238	-27,932	263
Income(loss) before income tax	-243,827	1,148,286	-120,600	534,414
Income tax expense(credit)	-44,160	345,894	-1,661	215,732
Net Income(loss)	-199,667	802,392	-118,939	318,682
Other Comprehensive income	'	'	'	'
Foreign Currency Translation adjustment	124,477	-30,900	437,827	202,924
Comprehensive income(loss)	($75,190)	$771,492	$318,888	$521,606
Basic and diluted income(loss) per share (in dollars per share)	($0.01)	$0.06	($0.01)	$0.02
Basic and diluted weighted average shares outstanding (in shares)	14,728,111	13,569,415	14,728,111	13,470,734

CONSOLIDATED_STATEMENT_OF_CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	6 Months Ended
CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities	'	'
Net income(loss)	($118,939)	$318,682
Adjustments to reconcile net income(loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	305,062	284,088
Accrued and imputed interest- related party	26,936	0
Stock issued for services	0	215,000
Deferred tax assets	-1,661	215,732
Changes in operating assets and liabilities:	'	'
Accounts receivable	1,754,359	-78,152
Inventory	367,729	-36,121
Advances to supplies	6,949	76,697
Prepaid expenses and other assets	-30,602	193,571
Accounts payable	-347,168	-262,644
Accrued expenses and tax payables	-602,284	-605,646
Net cash provided by operating activities	1,360,381	321,207
Cash flows from investing activities	'	'
Purchase of intangible asset	0	-1,129,237
Refund(Payment) of contract deposit	-1,575,593	712,702
Net cash used in investing activities	-1,575,593	-416,535
Cash flows from financing activities	'	'
Proceeds from related party loans	177,200	161,197
Net cash provided by financing activities	177,200	161,197
Effect of exchange rate changes on cash	2,104	5,284
Net increase (decrease) in cash	-35,908	71,153
Cash, beginning of the period	80,618	23,508
Cash, end of the period	44,710	94,661
Supplemental cash flow information	'	'
Cash paid for income taxes	0	0
Cash paid for interest	0	0
Supplemental disclosure of cash flow information	'	'
Transfer from contract deposit to intangible assets	$0	$216,978

ORGANIZATION_AND_BASIS_OF_PRES

ORGANIZATION AND BASIS OF PRESENTATION	6 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business Description and Basis Of Presentation [Text Block]	'
	1. ORGANIZATION AND BASIS OF PRESENTATION

	Tongli Pharmaceuticals (USA), Inc.(the “Company”), through an indirect wholly-owned subsidiary, Harbin Tianmu Pharmaceuticals Co., Ltd. (“Tianmu Pharmaceuticals”), develops, produces and sells a wide variety of pharmaceuticals and healthcare products in the People’s Republic of China (“PRC” or “China”) that are based on traditional Chinese medicine (“TCM”). In August 2011, the Company formed Harbing Lvnong Plant Ltd. (“Lvnong”) to plant and sell herbs in China. Lvnong is 100% owned by the Company’s indirect wholly-owned subsidiary, Heilongjiang Tongli Technology Co., Ltd. (“Tongli Technology”).

	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year or any other periods. The information included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2013.

	The balance sheet as of March 31, 2013 has been derived from the audited financial statements of the Company as of that date, but does not include all of the information and footnotes required by U.S. GAAP for the complete financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	Principles of consolidation

	The consolidated financial statements include the accounts of: (i) the Company (ii) the Company’s wholly owned subsidiary American Tony Pharmaceuticals, Inc., a Delaware corporation (“American Tony”), (iii) American Tony’s wholly owned subsidiary Tongli Technology, and (iv) Tongli Technology’s wholly owned subsidiaries, Tianmu Pharmaceuticals and Lvnong, each PRC companies. All significant inter-company accounts and transactions have been eliminated upon consolidation.

	Uses of estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. Actual results could differ from those estimates.

	Fair Value of Financial Instruments

	The Company adopted ASC 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data.

	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

	The carrying amounts reported in the balance sheets for cash, accounts receivable, inventory, prepaid expense, accounts payable and other accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC 820.

	Inventory

	Inventory is stated at the lower of cost, determined using the weighted average cost method, and net realizable value. Costs include materials, labor and manufacturing overhead. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose. Management periodically compares the cost of inventory with the market value and an allowance is made for writing down the inventory to its market value, if lower than cost. No allowance for inventory markdown is considered necessary for three and six months ended September 30, 2013 and 2012.

	Harvested Chinese herbs inventories are stated at lower of cost or market. Cost of growing herbs includes director labor and material costs accumulated through the balance sheet date.

	Impairment of Long Lived Assets

	Long-lived assets, which include property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the assets.

	The Company accounts for the impairment of long-lived assets in accordance with the guidance of FASB ASC 360-10-20. Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. Based on its review, the Company believes that, as of September 30, 2013, there were no impairment of its long-lived assets.

	Deferred income taxes

	The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” which requires that deferred tax assets and liabilities be recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. In addition, ASC 740 requires recognition of future tax benefits, such as carry-forwards, to the extent that realization of such benefits is more likely than not and that a valuation allowance be provided when it is more likely than not that some portion of the deferred tax asset will not be realized. Management reviews this valuation allowance periodically and makes adjustments as warranted.

	Foreign currency translation

	Since the Company operates primarily in the PRC, the Company’s functional currency is the Chinese Renminbi (“RMB”). For financial reporting purposes, RMB has been translated into United States dollars (“USD”) as the reporting currency. Equity accounts are translated at historical rates. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders' equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency translations are included in accumulated other comprehensive income.

	Revenue Recognition

	Revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, and no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers. The Company sells primarily to distributors who subsequently sell the merchandise. The agreements with distributors do not provide for the right of return. Return from distributors has historically been immaterial and accordingly no reserve is deemed necessary as of September 30, 2013 and 2012.

INVENTORY

INVENTORY	6 Months Ended
INVENTORY	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	3. INVENTORY

	As of September 30, 2013 and March 31, 2013, inventory consists the following:

			September 30, 2013		March 31, 2013
	Raw materials	$	11,555	$	14,019
	Finished goods		15,062		375,109
	Total	$	26,617	$	389,128

CONTRACT_DEPOSIT

CONTRACT DEPOSIT	6 Months Ended
CONTRACT DEPOSIT	Sep. 30, 2013
Banking and Thrift [Abstract]	'
Deposit Liabilities Disclosures [Text Block]	'
	4. CONTRACT DEPOSIT

	Contract deposit represents payments under material contracts by which the Company intends to purchase drug formula to be used in the manufacturing and increasing its product lines.

	As of September 30, 2013 and March 31, 2013, contract deposit consists the following:

		September 30, 2013		March 31, 2013
	Contract deposit-Ginshenwubao (1)	$	2,118,506	$	2,074,490
	Contract deposit-qiangshu(2)		3,014,797		2,952,159
	Contract deposit-yinge(3)		3,014,797		2,952,159
	Contract deposit-Zexiejuemingzi(4)		1,010,364		303,195
	Contract deposit-Songezhenzhu(5)		1,375,399		478,728
			10,533,864		8,760,731
	Less: current portion		-		-
	Total	$	10,533,864	$	8,760,731

	(1) On August 10, 2012, the Company entered into Ginshenwubao purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture Ginshenwubao at the total purchase price of RMB13,000,000 (approximately $2.06 million). Between August 10, 2012 and March 31, 2013, the Company paid RMB13,000,000(approximately to $2.07 million).The Company manufactured samples of this product using a subcontractor in the United States in November 2012 in order to provide samples to potential customers. The Company expected to market Ginshenwubao during 2014. The reason to postpone marketing Ginshenwubao is mainly due to the inspection of entire pharmaceutical industry by China government that effects on the marketing process.

	(2) On November 1, 2012, the Company entered into Qiangshu purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Qiangshu at the total purchase price of RMB18,500,000 (approximately $2.94 million). As of March 31, 2013, the Company paid the full amount of RMB18,500,000 (approximately $2.95 million). The application for the trademark of Qiangshu is under review by United States Patent and Trademark Office at the date of the report.

	(3) On December 18, 2012, the Company entered into Yinge purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Yinge at the total purchase price of RMB18,500,000 (approximately $2.94 million). As of March 31, 2013, 2013, the Company paid the full amount of RMB18,500,000 (approximately $2.95 million). The application for the trademark of Yinge is under review by United States Patent and Trademark Office at the date of the report.

	(4) On March 1, 2013, the Company entered into Zexiejuemingzi purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Zexiejuemingzi at the total purchase price of RMB12,000,000 (approximately $1.91 million). The Company paid RMB1.900,000 (approximately $0.30 million) as the deposit at the closing of Zexiejuemingzi purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,500,000(approximately $0.40 million) in April 2013 and RMB1,800,000(approximately $0.29 million) in July 2013. The trademark name of Zexiejuemingzi is Xie Jve Wu. As the date of the report, the trademark application is under review by United States Patent and Trademark Office.

	(5) On March 1, 2013, the Company entered into Songgezhenzhu purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Songgezhenzhu at the total purchase price of RMB16,000,000 (approximately $2.55 million). The Company paid RMB3,000,000 (approximately $0.48 million) as the deposit at the closing of Songgezhenzhu purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,300,000(approximately $0.37 million) in April 2013 and RMB3,140,000(approximately $0.51 million) in July and August 2013. The trademark name of Songezhenzhu is Shen Qi. As the date of the report, the trademark application is under review by United States Patent and Trademark Office.

DUE_TOFROM_RELATED_PARTIES

DUE TO(FROM) RELATED PARTIES	6 Months Ended
DUE TO(FROM) RELATED PARTIES	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	5. DUE TO(FROM) RELATED PARTIES

	Due to/(from) related parties consist of the following:

		September 30, 2013		March 31, 2013
	Due from Harbin Tianmu Real Estate Development Co. Ltd (a)	$	-410,111	$	-401,590
	Due to Yao, Mingli, Chairman of the Company		580,178		534,075
	Due to(from) US Hua Sky International Investment LLC (b)		-26,302		-24,576
	Due from Tianmu Investment Co. Ltd (c)		-5,003		-4,899
	Due to(from) Yao, Yuan, a shareholder of the Company (d)		293,131		158,186
	Total	$	431,893	$	261,196

	(a) Harbin Tianmu Real Estate Development Co., Ltd. is an entity owned by our Chairman, Mr. Mingli Yao.
	(b) US Hua Sky International Investment LLC is an entity owned by our Chairman, Mr. Mingli Yao
	(c)Tianmu Investment Co., Ltd. is an entity partially owned by our Chairman, Mr. Mingli Yao.
	(d) Ms. Yuan Yao is the daughter of Mr. Mingli Yao.

	Mr. Mingli Yao and Ms.Yuan Yao have personally guaranteed the loan receivable from Harbin Tianmu Real Estate Development Co. Ltd, US Hua Sky International Investment LLc and Tianmu Investment Co. Ltd. If the loans have not been repaid in the year ended March 31, 2014, Mr. Yao and Ms.Yao have agreed to offset the balance due to them referenced above.

	Amounts due to shareholders are non-interest bearing and due on demand. Interests on the loan balances were imputed at7% annual interest rate and recorded in additional paid in capital.

TAXES

TAXES	6 Months Ended
TAXES	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	6. TAXES

	(a) Corporation income tax (“CIT”)

	The Company’s Chinese subsidiaries are governed by the Income Tax Law of the People’s Republic of China concerning the private-run enterprises, which are generally subject to tax at a new statutory rate of 25%. As of September 30, 2013, for the Company’s PRC entities remain open for statutory examination by PRC tax authorities.

	The Company is incorporated in the United States. It had net operating loss carry forwards for United States income tax purposes amounted to $2,259,996 and $2,146,041 for the six months ended September 30, 2013 and the year ended March 31, 2013, respectively, which may be available to reduce future years' taxable income in the United States. These carry forwards will expire between 2028 and 2030. Management doesn't expect to generate any net income in the United States in the foreseeable future. Accordingly, the Company recorded a full valuation allowance as of September 30, 2013 and March 31, 2013.

	The reconciliation of income tax expense at the U.S. statutory rate at 35% in 2013 and 2012, to the Company’s effective tax is as follows:

		September 30, 2013		September 30, 2012
	U.S. Statutory income tax rate	$	-42,210	$	187,045
	Taxable difference between U.S. and China		665		-84,670
	Change in valuation allowance		39,884		113,357
	Effective income tax	$	-1,661	$	215,732

	The provisions for income taxes for the six months ended September 30, 2013 and 2012 are summarized as follows:

		September 30, 2013		September 30, 2012
	Current	$	-	$	-
	Deferred - United States		-39,884		-109,298
	Deferred - China		-1,661		211,673
	Change in Valuation Allowance		39,884		113,357
	Total	$	-1,661	$	215,732

	The components of income (loss) before income taxes from China and U.S. for the six months ended September 30, 2013 and 2012 were as follows:

		For the Six Months Ended September 30,
		2013		2012
	China	$	-6,645	$	666,696
	United States		-113,955		-132,282
	Income before income tax	$	-120,600	$	534,414

	(b) Value added tax (“VAT”)

	Enterprises or individuals who sell commodities, engage in repair and maintenance or import or export goods in the PRC are subject to a value added tax in accordance with the PRC laws. The value added tax standard rate is 17% of the gross sales price. A credit is available whereby VAT paid on the purchases of semi-finished products or raw materials used in the production of the Company’s finished products can be used to offset the VAT due on the sales of the finished products.

	(c) Other taxes

	The Company is also subject to 5% of business tax, 7% of City Construction Tax and 5% of Education Fees based on VAT.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	7. COMMITMENTS AND CONTINGENCIES

	On March 1, 2013, the Company entered into Zexiejuemingzi purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Zexiejuemingzi at the total purchase price of RMB12,000,000 (approximately $1.91 million). The Company paid RMB1,900,000 (approximately $0.30 million) as the deposit at the closing of Zexiejuemingzi purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,500,000(approximately $0.40 million) in April 2013 and RMB1,800,000(approximately $0.29 million) in July 2013. The Company was obligated to pay RMB5,800,000 (approximately $0.95 million) under the purchase agreement as of the date of the report.

	On March 1, 2013, the Company entered into Songgezhenzhu purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Songgezhenzhu at the total purchase price of RMB16,000,000 (approximately $2.55 million). The Company paid RMB3,000,000 (approximately $0.48 million) as the deposit at the closing of Songgezhenzhu purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,300,000(approximately $0.37 million) in April 2013 and RMB3,140,000(approximately $0.51 million) in July and August 2013. The Company was obligated to pay RMB7,560,000(approximately $1.23 million) under the purchase agreement as of the date of the report.

CONCENTRATION_OF_CREDIT_RISKS

CONCENTRATION OF CREDIT RISKS	6 Months Ended
CONCENTRATION OF CREDIT RISKS	Sep. 30, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	8. CONCENTRATION OF CREDIT RISKS

	For the six months ended September 30, 2013, Radix Polygoni Capsule represented 100% of the total sales.

VULNERABILITY_DUE_TO_OPERATION

VULNERABILITY DUE TO OPERATIONS IN PRC	6 Months Ended
VULNERABILITY DUE TO OPERATIONS IN PRC	Sep. 30, 2013
Unusual Risk and Uncertainties [Abstract]	'
Unusual Risks and Uncertainties Disclosure [Text Block]	'
	9. VULNERABILITY DUE TO OPERATIONS IN PRC

	The Company’s operations may be adversely affected by significant political, economic and social uncertainties in the PRC. Although the PRC government has been pursuing economic reform policies for more than thirty years, no assurance can be given that the PRC government will continue to pursue such policies or that such policies may not be significantly altered, especially in the event of a change in leadership, social or political disruption or unforeseen circumstances affecting the PRC’s political, economic and social conditions. There is also no guarantee that the PRC government’s pursuit of economic reforms will be consistent or effective.

	Substantially all of the Company’s businesses are transacted in RMB, which is not freely convertible. The Peoples Bank of China or other banks are authorized to buy and sell foreign currencies at the exchange rates quoted by the Peoples Bank of China. Approval of foreign currency payments by the Peoples Bank of China or other institutions requires submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts.

	Since the Company has its primary operations in the PRC, the majority of its revenues will be settled in RMB, not U.S. Dollars. Due to certain restrictions on currency exchanges that exist in the PRC, the Company’s ability to use revenue generated in RMB to pay any dividend payments to its shareholders outside of China may be limited.

	The Company’s business depends on maintaining licenses of its current products from SFDA. Obtaining licenses for additional products can be expensive and is usually time consuming. Failure to obtain the required licenses can cause the Company’s business plan to be delayed. If the delays prevent the Company from generating positive cash flows or introducing a significant number of products, there will be a material adverse effect on the Company.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	10. SUBSEQUENT EVENTS

	The Company has evaluated events after the date of these financial statements through the date that these financial statements were issued and no subsequent event is required to be disclosed.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of consolidation

	The consolidated financial statements include the accounts of: (i) the Company (ii) the Company’s wholly owned subsidiary American Tony Pharmaceuticals, Inc., a Delaware corporation (“American Tony”), (iii) American Tony’s wholly owned subsidiary Tongli Technology, and (iv) Tongli Technology’s wholly owned subsidiaries, Tianmu Pharmaceuticals and Lvnong, each PRC companies. All significant inter-company accounts and transactions have been eliminated upon consolidation.

Use of Estimates, Policy [Policy Text Block]	'
	Uses of estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments

	The Company adopted ASC 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data.

	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

	The carrying amounts reported in the balance sheets for cash, accounts receivable, inventory, prepaid expense, accounts payable and other accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC 820.

Inventory, Policy [Policy Text Block]	'
	Inventory

	Inventory is stated at the lower of cost, determined using the weighted average cost method, and net realizable value. Costs include materials, labor and manufacturing overhead. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose. Management periodically compares the cost of inventory with the market value and an allowance is made for writing down the inventory to its market value, if lower than cost. No allowance for inventory markdown is considered necessary for three and six months ended September 30, 2013 and 2012.

	Harvested Chinese herbs inventories are stated at lower of cost or market. Cost of growing herbs includes director labor and material costs accumulated through the balance sheet date.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of Long Lived Assets

	Long-lived assets, which include property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the assets.

	The Company accounts for the impairment of long-lived assets in accordance with the guidance of FASB ASC 360-10-20. Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. Based on its review, the Company believes that, as of September 30, 2013, there were no impairment of its long-lived assets.

Income Tax, Policy [Policy Text Block]	'
	Deferred income taxes

	The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” which requires that deferred tax assets and liabilities be recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. In addition, ASC 740 requires recognition of future tax benefits, such as carry-forwards, to the extent that realization of such benefits is more likely than not and that a valuation allowance be provided when it is more likely than not that some portion of the deferred tax asset will not be realized. Management reviews this valuation allowance periodically and makes adjustments as warranted.

Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign currency translation

	Since the Company operates primarily in the PRC, the Company’s functional currency is the Chinese Renminbi (“RMB”). For financial reporting purposes, RMB has been translated into United States dollars (“USD”) as the reporting currency. Equity accounts are translated at historical rates. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders' equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency translations are included in accumulated other comprehensive income.

Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition

	Revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, and no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers. The Company sells primarily to distributors who subsequently sell the merchandise. The agreements with distributors do not provide for the right of return. Return from distributors has historically been immaterial and accordingly no reserve is deemed necessary as of September 30, 2013 and 2012.

INVENTORY_Tables

INVENTORY (Tables)	6 Months Ended
INVENTORY (Tables)	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	As of September 30, 2013 and March 31, 2013, inventory consists the following:

			September 30, 2013		March 31, 2013
	Raw materials	$	11,555	$	14,019
	Finished goods		15,062		375,109
	Total	$	26,617	$	389,128

CONTRACT_DEPOSIT_Tables

CONTRACT DEPOSIT (Tables)	6 Months Ended
CONTRACT DEPOSIT (Tables)	Sep. 30, 2013
Banking and Thrift [Abstract]	'
Contract Deposit Assets Disclosures [Table Text Block]	'
	As of September 30, 2013 and March 31, 2013, contract deposit consists the following:

		September 30, 2013		March 31, 2013
	Contract deposit-Ginshenwubao (1)	$	2,118,506	$	2,074,490
	Contract deposit-qiangshu(2)		3,014,797		2,952,159
	Contract deposit-yinge(3)		3,014,797		2,952,159
	Contract deposit-Zexiejuemingzi(4)		1,010,364		303,195
	Contract deposit-Songezhenzhu(5)		1,375,399		478,728
			10,533,864		8,760,731
	Less: current portion		-		-
	Total	$	10,533,864	$	8,760,731

	(1) On August 10, 2012, the Company entered into Ginshenwubao purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture Ginshenwubao at the total purchase price of RMB13,000,000 (approximately $2.06 million). Between August 10, 2012 and March 31, 2013, the Company paid RMB13,000,000(approximately to $2.07 million).The Company manufactured samples of this product using a subcontractor in the United States in November 2012 in order to provide samples to potential customers. The Company expected to market Ginshenwubao during 2014. The reason to postpone marketing Ginshenwubao is mainly due to the inspection of entire pharmaceutical industry by China government that effects on the marketing process.

	(2) On November 1, 2012, the Company entered into Qiangshu purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Qiangshu at the total purchase price of RMB18,500,000 (approximately $2.94 million). As of March 31, 2013, the Company paid the full amount of RMB18,500,000 (approximately $2.95 million). The application for the trademark of Qiangshu is under review by United States Patent and Trademark Office at the date of the report.

	(3) On December 18, 2012, the Company entered into Yinge purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Yinge at the total purchase price of RMB18,500,000 (approximately $2.94 million). As of March 31, 2013, 2013, the Company paid the full amount of RMB18,500,000 (approximately $2.95 million). The application for the trademark of Yinge is under review by United States Patent and Trademark Office at the date of the report.

	(4) On March 1, 2013, the Company entered into Zexiejuemingzi purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Zexiejuemingzi at the total purchase price of RMB12,000,000 (approximately $1.91 million). The Company paid RMB1.900,000 (approximately $0.30 million) as the deposit at the closing of Zexiejuemingzi purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,500,000(approximately $0.40 million) in April 2013 and RMB1,800,000(approximately $0.29 million) in July 2013. The trademark name of Zexiejuemingzi is Xie Jve Wu. As the date of the report, the trademark application is under review by United States Patent and Trademark Office.

	(5) On March 1, 2013, the Company entered into Songgezhenzhu purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Songgezhenzhu at the total purchase price of RMB16,000,000 (approximately $2.55 million). The Company paid RMB3,000,000 (approximately $0.48 million) as the deposit at the closing of Songgezhenzhu purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,300,000(approximately $0.37 million) in April 2013 and RMB3,140,000(approximately $0.51 million) in July and August 2013. The trademark name of Songezhenzhu is Shen Qi. As the date of the report, the trademark application is under review by United States Patent and Trademark Office.

DUE_TOFROM_RELATED_PARTIES_Tab

DUE TO(FROM) RELATED PARTIES (Tables)	6 Months Ended
DUE TO(FROM) RELATED PARTIES (Tables)	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Due to/(from) related parties consist of the following:

		September 30, 2013		March 31, 2013
	Due from Harbin Tianmu Real Estate Development Co. Ltd (a)	$	-410,111	$	-401,590
	Due to Yao, Mingli, Chairman of the Company		580,178		534,075
	Due to(from) US Hua Sky International Investment LLC (b)		-26,302		-24,576
	Due from Tianmu Investment Co. Ltd (c)		-5,003		-4,899
	Due to(from) Yao, Yuan, a shareholder of the Company (d)		293,131		158,186
	Total	$	431,893	$	261,196

	(a) Harbin Tianmu Real Estate Development Co., Ltd. is an entity owned by our Chairman, Mr. Mingli Yao.
	(b) US Hua Sky International Investment LLC is an entity owned by our Chairman, Mr. Mingli Yao
	(c)Tianmu Investment Co., Ltd. is an entity partially owned by our Chairman, Mr. Mingli Yao.
	(d) Ms. Yuan Yao is the daughter of Mr. Mingli Yao.

TAXES_Tables

TAXES (Tables)	6 Months Ended
TAXES (Tables)	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The reconciliation of income tax expense at the U.S. statutory rate at 35% in 2013 and 2012, to the Company’s effective tax is as follows:

		September 30, 2013		September 30, 2012
	U.S. Statutory income tax rate	$	-42,210	$	187,045
	Taxable difference between U.S. and China		665		-84,670
	Change in valuation allowance		39,884		113,357
	Effective income tax	$	-1,661	$	215,732

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	The provisions for income taxes for the six months ended September 30, 2013 and 2012 are summarized as follows:

		September 30, 2013		September 30, 2012
	Current	$	-	$	-
	Deferred - United States		-39,884		-109,298
	Deferred - China		-1,661		211,673
	Change in Valuation Allowance		39,884		113,357
	Total	$	-1,661	$	215,732

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	'
	The components of income (loss) before income taxes from China and U.S. for the six months ended September 30, 2013 and 2012 were as follows:

		For the Six Months Ended September 30,
		2013		2012
	China	$	-6,645	$	666,696
	United States		-113,955		-132,282
	Income before income tax	$	-120,600	$	534,414

ORGANIZATION_AND_BASIS_OF_PRES1

ORGANIZATION AND BASIS OF PRESENTATION (Details Textual) (Heilongjiang Tongli Technology Co., Ltd. [Member])	Sep. 30, 2013
Heilongjiang Tongli Technology Co., Ltd. [Member]	'
Noncontrolling Interest, Ownership Percentage by Parent	100.00%

INVENTORY_Details

INVENTORY (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Raw materials	$11,555	$14,019
Finished goods	15,062	375,109
Total	$26,617	$389,128

CONTRACT_DEPOSIT_Details

CONTRACT DEPOSIT (Details) (USD $)	Sep. 30, 2013		Mar. 31, 2013
Contract Deposit	$10,533,864		$8,760,731
Less: current portion	0		0
Total	10,533,864		8,760,731
Ginshenwubao [Member]	'		'
Contract Deposit	2,118,506	[1]	2,074,490	[1]
Qiangshu [Member]	'		'
Contract Deposit	3,014,797	[2]	2,952,159	[2]
Yinge [Member]	'		'
Contract Deposit	3,014,797	[3]	2,952,159	[3]
Zexiejuemingzi [Member]	'		'
Contract Deposit	1,010,364	[4]	303,195	[4]
Songezhenzhu [Member]	'		'
Contract Deposit	$1,375,399	[5]	$478,728	[5]

[1]	On August 10, 2012, the Company entered into Ginshenwubao purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture Ginshenwubao at the total purchase price of RMB13,000,000 (approximately $2.06 million). Between August 10, 2012 and March 31, 2013, the Company paid RMB13,000,000(approximately to $2.07 million).The Company manufactured samples of this product using a subcontractor in the United States in November 2012 in order to provide samples to potential customers. The Company expected to market Ginshenwubao during 2014. The reason to postpone marketing Ginshenwubao is mainly due to the inspection of entire pharmaceutical industry by China government that effects on the marketing process.
[2]	On November 1, 2012, the Company entered into Qiangshu purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Qiangshu at the total purchase price of RMB18,500,000 (approximately $2.94 million). As of March 31, 2013, the Company paid the full amount of RMB18,500,000 (approximately $2.95 million). The application for the trademark of Qiangshu is under review by United States Patent and Trademark Office at the date of the report.
[3]	On December 18, 2012, the Company entered into Yinge purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Yinge at the total purchase price of RMB18,500,000 (approximately $2.94 million). As of March 31, 2013, 2013, the Company paid the full amount of RMB18,500,000 (approximately $2.95 million). The application for the trademark of Yinge is under review by United States Patent and Trademark Office at the date of the report.
[4]	On March 1, 2013, the Company entered into Zexiejuemingzi purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Zexiejuemingzi at the total purchase price of RMB12,000,000 (approximately $1.91 million). The Company paid RMB1.900,000 (approximately $0.30 million) as the deposit at the closing of Zexiejuemingzi purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,500,000(approximately $0.40 million) in April 2013 and RMB1,800,000(approximately $0.29 million) in July 2013. The trademark name of Zexiejuemingzi is Xie Jve Wu. As the date of the report, the trademark application is under review by United States Patent and Trademark Office.
[5]	On March 1, 2013, the Company entered into Songgezhenzhu purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the product Songgezhenzhu at the total purchase price of RMB16,000,000 (approximately $2.55 million). The Company paid RMB3,000,000 (approximately $0.48 million) as the deposit at the closing of Songgezhenzhu purchase agreement in March 2013. The balance of the purchase price will be paid in installments according to the progress of performance under the contract. The Company paid RMB2,300,000(approximately $0.37 million) in April 2013 and RMB3,140,000(approximately $0.51 million) in July and August 2013. The trademark name of Songezhenzhu is Shen Qi. As the date of the report, the trademark application is under review by United States Patent and Trademark Office.

CONTRACT_DEPOSIT_Details_Textu

CONTRACT DEPOSIT (Details Textual)

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

2 Months Ended

6 Months Ended

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Jul. 31, 2013

Apr. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Apr. 30, 2013

Mar. 31, 2013

Aug. 31, 2013

Sep. 30, 2013

Ginshenwubao Purchase Agreement [Member]

Qiangshu Purchase Agreement [Member]

Yinge Purchase Agreement [Member]

Zexiejuemingzi Purchase Agreement [Member]

Songezhenzhu Purchase Agreement [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Long Term Contracts Or Programs Name Of Contractor

'Harbin Junde Healthcare Product Company

Long Term Contracts Or Programs Date Of Contract Entered

10-Aug-12

1-Nov-12

18-Dec-12

1-Mar-13

Long Term Contracts Or Programs Purchase Price

$2,060,000

13,000,000

$2,940,000

18,500,000

$2,940,000

18,500,000

$290,000

1,800,000

$400,000

2,500,000

$300,000

1,900,000

$1,910,000

12,000,000

$370,000

2,300,000

$480,000

3,000,000

$510,000

3,140,000

$2,550,000

16,000,000

Payments For Contract Deposits

$2,070,000

13,000,000

$2,950,000

18,500,000

$2,950,000

18,500,000

DUE_TOFROM_RELATED_PARTIES_Det

DUE TO(FROM) RELATED PARTIES (Details) (USD $)	Sep. 30, 2013		Mar. 31, 2013
Due to/(from) related parties, Total	$431,893		$261,196
Harbin Tianmu Real Estate Development Co. Ltd [Member]	'		'
Due to/(from) related parties, Total	-410,111	[1]	-401,590	[1]
Yao, Mingli, Chairman Of Company [Member]	'		'
Due to/(from) related parties, Total	580,178		534,075
US Hua Sky International Investment LLC [Member]	'		'
Due to/(from) related parties, Total	-26,302	[2]	-24,576	[2]
Tianmu Investment Co. Ltd [Member]	'		'
Due to/(from) related parties, Total	-5,003	[3]	-4,899	[3]
Yao, Yuan, Shareholder of the Company [Member]	'		'
Due to/(from) related parties, Total	$293,131	[4]	$158,186	[4]

[1]	Harbin Tianmu Real Estate Development Co., Ltd. is an entity owned by our Chairman, Mr. Mingli Yao.
[2]	US Hua Sky International Investment LLC is an entity owned by our Chairman, Mr. Mingli Yao
[3]	Tianmu Investment Co., Ltd. is an entity partially owned by our Chairman, Mr. Mingli Yao.
[4]	Ms. Yuan Yao is the daughter of Mr. Mingli Yao.

DUE_TOFROM_RELATED_PARTIES_Det1

DUE TO(FROM) RELATED PARTIES (Details Textual)	6 Months Ended
DUE TO(FROM) RELATED PARTIES (Details Textual)	Sep. 30, 2013
Interest Percentage On Loan By Related Parties	7.00%

TAXES_Details

TAXES (Details) (USD $)	3 Months Ended		6 Months Ended
TAXES (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
U.S. Statutory income tax rate	'	'	($42,210)	$187,045
Taxable difference between U.S. and China	'	'	665	-84,670
Change in valuation allowance	'	'	39,884	113,357
Effective income tax	($44,160)	$345,894	($1,661)	$215,732

TAXES_Details_1

TAXES (Details 1) (USD $)	3 Months Ended		6 Months Ended
TAXES (Details 1) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Current	'	'	$0	$0
Deferred - United States	'	'	-39,884	-109,298
Deferred - China	'	'	-1,661	211,673
Change in Valuation Allowance	'	'	39,884	113,357
Total	($44,160)	$345,894	($1,661)	$215,732

TAXES_Details_2

TAXES (Details 2) (USD $)	3 Months Ended		6 Months Ended
TAXES (Details 2) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
China	'	'	($6,645)	$666,696
United States	'	'	-113,955	-132,282
Income before income tax	($243,827)	$1,148,286	($120,600)	$534,414

TAXES_Details_Textual

TAXES (Details Textual) (USD $)	6 Months Ended
TAXES (Details Textual) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Effective Income Tax Rate Reconciliation, Tax Settlements	25.00%	'	'
Operating Loss Carryforwards	$2,259,996	'	$2,146,041
Operating Loss Carryforwards, Expiration Dates	'These carry forwards will expire between 2028 and 2030.	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	35.00%	35.00%	'
Value Added Tax Rate	17.00%	'	'
Business Tax Rate	5.00%	'	'
City Construction Tax Rate	7.00%	'	'
Education Fees Based On VAT Rate	5.00%	'	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Textual)

1 Months Ended

6 Months Ended

1 Months Ended

2 Months Ended

6 Months Ended

Jul. 31, 2013

Apr. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Apr. 30, 2013

Mar. 31, 2013

Aug. 31, 2013

Sep. 30, 2013

Zexiejuemingzi Purchase Agreement [Member]

Songezhenzhu Purchase Agreement [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Long Term Contracts Or Programs Name Of Contractor

'Harbin Junde Healthcare Product Company

Long Term Contracts Or Programs Date Of Contract Entered

1-Mar-13

Long Term Contracts Or Programs Purchase Price

$290,000

1,800,000

$400,000

2,500,000

$300,000

1,900,000

$1,910,000

12,000,000

$370,000

2,300,000

$480,000

3,000,000

$510,000

3,140,000

$2,550,000

16,000,000

Long Term Contracts Or Programs Obligation Purchase Price

$950,000

5,800,000

$1,230,000

7,560,000

CONCENTRATION_OF_CREDIT_RISKS_

CONCENTRATION OF CREDIT RISKS (Details Textual) (Radix Polygoni Capsule [Member], Product Concentration Risk [Member])	6 Months Ended
	Sep. 30, 2013
Radix Polygoni Capsule [Member] \| Product Concentration Risk [Member]	'
Concentration Risk, Percentage	100.00%